How remember, some years are expected outcomes the trial of the company Alba Therapeutics 
The purpose of the experiment was to determine whether this peptide was able to inhibit the production of Zonulin for a certain period in order to prevent the crossing of the floor intestinal gluten through "tight junctions " (areas of union between two cells) and trigger the immune response in celiac patients.
As reported by the U.S. site of ClinicTrials a registry on clinical trials conducted in the United States and around the world, it seems that the first test is now concluded, even if they are not yet published the results.
The first rumors about the trial results were not particularly exciting [1]. It speaks of disappointed expectations [2] on the reduction of intestinal permeability and, as a result of this, the pharmaceutical giant Shire had withdrawn from the purchase of the rights of the pill, still in possession of Dawn Therapeutics.
I have therefore asked Professor Alessio Fasano, director of research center of pediatric gastroenterology at the University of Maryland (USA) who has conducted the first studies sull'AT1001 a statement on the outcome of the trial because, although not personally involved in this last phase, still have access to the data provided directly by Dr. Francisco Leon, the coordinator of the trial of Alba.
Here is an excerpt of the interview significantly:
" The study had as 'read out' primary the change of intestinal permeability, measured as the ratio of urinary lactulose / mannitol. As you mentioned, in this trial have not seen differences in intestinal permeability between the placebo and Larazotide group (the name given pharmaceutical all'AT1001).
We are having significant differences on symptoms (gluten + placebo group had more frequent symptoms that the group Larazotide gluten +) and, more importantly, significant differences in appearance of anti-tissue transglutaminase ( tTG) , which were elevated in the placebo group but remained normal in the group Larazotide. Therefore, even if the primary endpoint did not differ, in fact, the pill has already confirmed its efficacy seen in previous trials . "
governing ventilation Shire news on the withdrawal of the options on T. Alba, you do not have definite information. However, if this approach were confirmed, the reasons may be different, not necessarily linked to outcomes in the trial.
It 'clear that these stories reassure us, especially on the evidence of non-appearance in subjects treated with the antibody Larazotide (AT1001).
Although the primary endpoint showed no difference significant between the control group treated with placebo and the experimental drugs such as lactulose and mannitol, it is also true that the focal point remains the fact that the drug can actually block the inflammatory effects of gluten in celiac disease.
E 'of March 2009 reported that Alba Therapeutics has initiated further studies on new and Larazotide Acetate (AT1001) [3], thus confirming the hopes that this substance can lead to the effective production of a protective pill for celiac disease.
APGuarino
[1] http://celiacdisease.about.com/b/2009/10/31/setback-for-potential-celiac-disease-drug-at-1001.htm
[2] http://notonlyglutenfree.org/2010/02/at1001_disattende_le_aspettative.html
